We found that combined radiotherapy and CHK1 inhibition can promote a more favorable immune environment by increasing the presence of antigen-presenting dendritic cells and cytotoxic T cells, which are key players in antitumor immunity in ARID1A-deficient CRC tumors. This evidence concerns the gene ARID1A and colorectal carcinoma.